News & Events about Passage Bio Inc.
Globe Newswire
3 months ago
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (...
Globe Newswire
6 months ago
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will ...
Ticker Report
8 months ago
Zacks Investment Research cut shares of Passage Bio (NASDAQ:PASG Get Rating) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, Passage Bio Inc. is a genetic medicines company. It is focused on ...
Globe Newswire
9 months ago
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the ...